Who Qualifies for the New FDA PreCheck Pilot Program?

Why It Matters

By fast‑tracking new domestic facilities, the program strengthens U.S. drug supply resilience and reduces dependence on foreign manufacturers.

Key Takeaways

• Only brand‑new U.S. facilities qualify, extensions excluded
• Three‑year production commitment required after FDA approval
• Priority given to domestic raw material sourcing
• Essential medicines and shortage drugs receive higher selection scores
• Innovative modular or automated designs boost selection chances

Pulse Analysis

The FDA’s PreCheck Pilot Program represents the agency’s most aggressive effort yet to shore up domestic drug manufacturing. By opening submissions through March 1 2026, the agency signals that new, stand‑alone facilities built on U.S. soil will receive regulatory fast‑track support. The program’s two‑phase structure—initial eligibility screening followed by a detailed finalist review—mirrors earlier onshoring initiatives but adds concrete timelines and a clear commitment clause: facilities must remain operational for at least three years after approval. This framework aims to reduce the lag between construction and market entry, a chronic weakness in the U.S. supply chain.

Eligibility hinges on four non‑negotiable rules: the plant must be brand‑new, located within the United States or its territories, sized to meet a defined market need, and willing to file a new NDA, ANDA, BLA or Type II DMF within the program. Notably, the FDA treats adjacent buildings as a single facility, so expanding an existing campus does not qualify. Selection, however, rewards projects that source key starting materials domestically, target essential or shortage medicines, and incorporate innovative construction methods such as modular or prefabricated units. Contract manufacturers can participate if they partner with an experienced sponsor, widening the pool of eligible applicants.

If the initial cohort of seven facilities proves successful, the PreCheck model could become a template for future regulatory incentives, potentially reshaping the U.S. pharmaceutical landscape. Faster time‑to‑market for critical therapies would mitigate recent drug shortages and enhance national security by limiting reliance on foreign suppliers. Moreover, the program’s emphasis on advanced automation and digital integration aligns with the FDA’s broader Advanced Manufacturing Technology initiatives, encouraging industry investment in next‑generation production. Companies that secure a PreCheck slot may also gain early insight into evolving compliance expectations, giving them a competitive edge as additional cohorts roll out.